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Bile acids at the cross-roads of gut 
microbiome–host cardiometabolic interactions
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Abstract 
While basic and clinical research over the last several decades has recognized a number of modifiable risk factors 
associated with cardiometabolic disease progression, additional and alternative biological perspectives may offer 
novel targets for prevention and treatment of this disease set. There is mounting preclinical and emerging clinical 
evidence indicating that the mass of metabolically diverse microorganisms which inhabit the human gastrointestinal 
tract may be implicated in initiation and modulation of cardiovascular and metabolic disease outcomes. The following 
review will discuss this gut microbiome–host metabolism axis and address newly proposed bile-mediated signaling 
pathways through which dysregulation of this homeostatic axis may influence host cardiovascular risk. With a central 
focus on the major nuclear and membrane-bound bile acid receptor ligands, we aim to review the putative impact 
of microbial bile acid modification on several major phenotypes of metabolic syndrome, from obesity to heart failure. 
Finally, attempting to synthesize several separate but complementary hypotheses, we will review current directions in 
preclinical and clinical investigation in this evolving field.
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Background
The human metagenome consists of the host genome 
and a symbiont microbiome of over 10 trillion bacteria 
predominantly located within the host gastrointestinal 
tract. Both genomes have co-evolved over millennia with 
the microbiome expressing a genetic diversity greater 
than that of the host [1]. The microbiome mass has been 
estimated at ~ 4 × 1013 [1], with distribution within the 
intestine highly segmented between the upper/small 
intestine and the large intestine [2]. Such segmenta-
tion of the predominant bacterial mass within the large 
intestine is likely a result of competitive evolutionary 
forces that have ensured the host has ‘first shot’ at dietary 
substrates. Interaction of the host/microbiome with the 
external environment through the ingestion of food thus 
plays a major role in determining the beneficial or det-
rimental effects of nature on human health [3]. In fact, 
during the post industrial age, the human microbiome 
has evolved to a much greater extent than the previous 4 
million years of hominid existence [4]. Thus, we stand at 
the threshold of a new era of discovery where fundamen-
tal insights into the nature of biologic interaction of our 
“other genome” with our own host physiology will illu-
minate new mechanisms of understanding of the role of 
environment in diseases of modern man. Nowhere is this 
more relevant than the cardiovascular system which is 
afflicted by a spectrum of diseases that have become the 
scourge of our increasingly narrow, high-calorie, high-
sugar and fat-rich ‘Western’ diet.
Seminal studies by Hazen and co-workers have already 
neatly highlighted the deleterious interaction between 
phosphatidylcholine in the human diet and expansion 
of selected gut bacteria that produce trimethylamine, 
which is further metabolized to trimethylamine-N-oxide, 
a metabolite that correlates with increased risk of cardi-
ovascular disease (CVD; [5–8]). Despite the compelling 
preclinical and clinical evidence now available, a recently 
published meta-analysis of 18,076 incident CVD events, 
5343 CVD deaths and 184,010 subjects revealed no sig-
nificant link between quaternary amine consumption 
and hard CVD outcomes (i.e. incidence and mortality) 
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[9]. With this in mind, and in the light of several recent 
extensive reviews on the trimethylamine-N-oxide path-
way, this aspect of the microbiome–cardiometabolic 
interaction will not be discussed further herein.
In this review, we intend to address another comple-
mentary aspect of the gut microbiome–host metabolism 
interaction, which is modulated centrally by microbial-
mediated bile acid modification. Herein, we examine 
the relationship of the gut microbiome to disease enti-
ties ranging from obesity, hyperlipidemia, insulin resist-
ance and hypertension (i.e. metabolic syndrome) through 
heart failure with preserved ejection fraction to athero-
sclerotic disease and complications of stroke, myocardial 
infarction and peripheral vascular disease. This review 
pulls from the modest cohort of randomized controlled 
trials currently available, which is supported by preclini-
cal mechanistic data and clinical observational studies 
of bariatric surgery patients. We aim to put into con-
text the most current knowledge on how the microbi-
ome, through bile acid manipulation, has the potential to 
impact on host cardiovascular and metabolic health in a 
manner which outlines not only pathways, but also the 
potential environmental aspects that contribute to this 
tipping-point and potential novel therapies that might 
derive from it.
Microbial bile modification
Bile acids have systemic applications that far surpass 
their mechanical role as intestinal detergents. The de 
novo synthesis of bile acids from cholesterol occurs 
in hepatocytes through two pathways, termed classi-
cal and alternative, which are facilitated by cytochrome 
P enzymes CYP7A1 and CYP27A1, respectively. In a 
homeostatic state, bile acids are recycled 4–12 times 
per day, with less than 5% of secreted bile acids being 
excreted. However, bile modification by members of 
the gut microbiome can greatly influence the efficacy at 
which these compounds are reabsorbed and recycled. 
Naïve conjugated bile salts, secreted into the descend-
ing duodenum, undergo several microbial modification 
reactions, the first of which involves deconjugation to 
primary bile acids by bile salt hydrolase (BSH) enzymes. 
This process involves the removal of an amine group, 
either taurine or glycine, from the conjugated bile salt. 
Bile salts can be highly cytotoxic to microorganisms, 
these enzymes therefore likely evolved as a detoxification 
mechanism and as such, are expressed in abundance by 
the major microbial phyla found in the human gastroin-
testinal tract [10]. This reaction ‘unlocks’ the sterol mol-
ecule to a plethora of downstream microbial enzymes, 
including 7α-dehydroxylase [11]. The detailed enzymatic 
processes of these reactions have been neatly reviewed 
and presented previously by Martin and colleagues [12]. 
Intriguingly, microbial enzymes have the potential to 
create dozens of different bile acid-derived molecules 
[13, 14], each with varying capacity to function as signal-
ing molecules within the host system. In addition, these 
modifications alter the reabsorptive capacity of bile acids 
leading to obligate excretion. Due to this central role of 
the gut microbiome in profoundly shaping the whole bile 
pool and the diversity of its profile, bile acids offer a con-
vincing pathway of microbe–host crosstalk in the context 
of overall host metabolism. In a clinical setting, bile acids 
may represent potential biomarkers of metabolic health 
and disease which are highly trackable through analytic 
techniques [15], while also providing several potentially 
potent pathways that may be targeted in the pursuit of 
novel therapeutics.
Bile modulates host metabolic function
The gut microbiome potentially represents a “bounty or 
burden” in terms of its metabolic capacity and how this 
impacts upon host cardiometabolic health. In line with 
this, the variety of microbes that humans host appear to 
have influence over virtually every metabolic process; alter-
ing adiposity, liver lipid metabolism and glucose metabo-
lism, as well as heart and vascular function [16]. Current 
research in the area of microbiome–host crosstalk impli-
cates a number of familiar metabolic groups in this inter-
dependency—including endotoxins, short-chain fatty acids, 
several neuroactive peptides and microbially-modified bile 
acids, amongst others. The significance of bile acids, of 
intestinal and hepatic origin, as paracrine and endocrine 
signaling molecules with systemic reach has only recently 
been highlighted [17]. These molecules impact signifi-
cantly on pathways intimately involved in inflammation, 
host lipid, cholesterol and glucose metabolism, while also 
demonstrating the potential to alter circadian rhythm [18] 
and immunity [19], in preclinical models. We now address 
some of the compelling preclinical and clinical data detail-
ing these intricate interactions (Table 1).
Weight management and obesity
Obesity represents a central facet of the metabolic syn-
drome and a preponderance of microbiome–host metab-
olism interaction studies have focused on it. One of the 
most important early clinical discoveries was that per-
turbations in the gut microbiome caused by antibiotic 
administration during early development can have last-
ing effects on both the composition and richness of the 
microbiome [20], with deleterious consequences for life-
long metabolic health of the host [21–24]. Microbiome 
richness, generally regarded as a proxy for its metabolic 
capabilities or functionality, has in turn been shown to 
correlate tightly with human inflammatory and metabolic 
markers [25].
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Some of the most convincing clinical data to indicate 
a role of the gut microbiome in obesity has arisen from 
bariatric surgery studies. The mechanism underlying effi-
cacy of these obesity-curbing surgeries, including verti-
cal sleeve gastrectomy and Roux-en Y gastric bypass, has 
long puzzled researchers. Observational clinical studies 
have catalogued the gut microbiome alterations observed 
in these patients, consistently reporting increased Pro-
teobacteria and decreased Bacteroides levels [26]. In 
addition, serum bile profiling reveals significant fluc-
tuation post vertical sleeve gastrectomy, including 
increased glycoursodeoxycholic acid (GUDCA) coupled 
with decreased glycocholic acid (GCA), taurocholic acid 
(TCA) and deoxycholic acid (DCA) [27]. Ryan et al. were 
first to highlight the role of microbial bile acid modifica-
tion in the beneficial effects of successful surgeries of this 
nature—i.e. those which led to significant weight/BMI 
reduction, improved lipid and glucose metabolism [28]. 
This group of investigators had previously demonstrated 
a positive relationship between satiety/weight-loss and 
expression of murine fibroblast growth factor (FGF) 15 
(equivalent to FGF19 in Man). FGF15 is a factor tightly 
modulated by the bile acid nuclear receptor farnesoid X 
receptor (FXR) [29], which is a critical intracellular sen-
sor regulating bile acid and cholesterol homeostasis [30]. 
This underscored a molecular rather than mechanical 
foundation for the efficacy of bariatric surgery, with bile 
acid signaling at the core [31]. Subsequent preclinical 
studies have further elaborated on this pathway [32–34], 
while several recent clinical trials have solidified the per-
ceived role of bile acid-FXR-FGF19 signaling in obesity 
[35–37].
In terms of the weight attenuating effects observed 
in mice, several groups have now pointed to the potent 
endogenous FXR antagonist, TβMCA, as a key modula-
tor of host adiposity. The Wallenberg Laboratory initially 
identified bile acid enrichment in the enterohepatic sys-
tem of germ-free mice, demonstrating additionally the 
regulation of bile acid synthesis through the FXR-FGF15 
axis [38]. The same group showed that microbiome-
mediated depletion of FXR antagonists, such as TβMCA, 
is implicated in obesity induced by high-fat diet [34]. 
Table 1 Bile acid receptors, ligands and cardiometabolic physiological effects
BAT brown adipose tissue, WAT white adipose tissue, T4 thyroxine, T3 triiodothyronine, GLP-1 glucagon-like peptide-1, TAG triacylglycerides, FFA free fatty acids, NEFA 
non-esterified fatty acids, RCT reverse cholesterol transport, NO nitric oxide, BP blood pressure, LOD limit of detection, N/A not applicable
Receptor Natural 
and synthetic 
ligands
Serum concen-
tration (nM) 
[107]
Relative 
potency
Reported physiological effects
Adiposity glucose 
metabolism
Lipid metabo-
lism
Vascular 
disease
HF and HTN
FXR CDCA 380 ↑ BAT [39] ↓ Glucose
↓ Insulin [147]
↓ TAG [147] ↑ RCT [86] ↓ BP [98]
CA 440
DCA 320
LCA < LOD
UDCA 43
WAY-362450 N/A – – ↓ TAG [148]
↓ Cholesterol 
[89, 149]
↓ Atherosclero-
sis [88, 89]
–
GW4064 N/A – ↑ Glycogen 
[150]
↑ Insulin sensi-
tivity [151]
↓ Glucose
↓ TAG/FFA
↓ Cholesterol 
[152–154]
↑ RCT [87] –
OCA N/A ↑ BAT
↓ WAT [113]
↓ Glucose [113] ↑ LDL [113]
↓ HDL [117]
↑ RCT [155] ↓ BP [78]
Fexaramine N/A ↑ BAT [52] ↓ Glucose
↓ Gluconeogen-
esis
↓ Insulin [52]
↓ Cholesterol 
[52]
– –
TGR5 LCA < LOD ↑ BAT
↑ T4 ⟶ T3 
[40]
↓ Glucose
↓ Insulin [40]
– ↑ NO
↓ Monocyte 
infiltration 
[94]
–
TLCA 0.33
CA 440
DCA 320
CDCA 380
6-EMCA/INT-777 N/A ↑ BAT
↓ WAT [156]
↑ GLP-1 [156] ↓ TAG/NEFA 
[156]
↓ Atheroscle-
rosis
↓ Foam cell [93]
–
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However, clinical relevance of these findings remains 
unclear, as TβMCA and related bile acids are not synthe-
sised in the human system.
Intriguingly, bile acids have also shown the propensity 
to impact upon mammalian energy expenditure through 
the thyroid system. Watanabe and colleagues first dem-
onstrated this effect in mice through application of the 
Takeda-G-protein-receptor 5 (TGR5) agonist, cholic 
acid (CA) [39]. The effects were deemed to be mediated 
by the induction of the cyclic-AMP-dependent thyroid 
hormone activating enzyme type 2 iodothyronine deio-
dinase, thereby increasing energy expenditure in brown 
adipose tissue (BAT). A small-scale randomized con-
trolled trial crossover study recently further explored the 
impact of a 2-day chenodeoxycholic acid (CDCA) oral 
intervention on BAT activity and energy expenditure 
in 12 healthy females [40]. The results indicated a sub-
stantial increase in both primary outcome parameters, 
which were determined by positron emission tomog-
raphy–computed tomography scan and serum thyroid 
hormones, respectively. The authors mined down to the 
relevant receptor activity through ex  vivo human BAT 
culture experiments with CDCA and specific bile acid 
receptor agonists, in which the G-protein coupled recep-
tor TGR5 was confirmed. TGR5 is one of several mem-
brane-bound receptors highly expressed in enterocytes of 
the ileum and colon, which is readily activated by several 
naïve and microbially-modified bile acids. These studies 
indicate a potential application of TGR5-agonists as anti-
obesogenic or indeed anti-diabetic pharmaceuticals, as 
BAT is known to stimulate insulin sensitivity [41].
Insulin secretion and sensitivity
The gut microbiome has been proposed as a highly sen-
sitive and specific tool for the identification of insulin 
insensitivity [42–44], although this is currently of lim-
ited clinical utility. The metabolic capacity of the gut 
microbiome appears to be fundamental to host glucose 
metabolism, with metabolites such as branched-chain 
amino acids [45] and succinate [46] most recently being 
reported as negatively and positively correlated with 
insulin sensitivity, respectively. Microbiome-mediated 
succinate production, for instance, was found to impact 
directly upon glucose homeostasis by inducing intestinal 
gluconeogenesis, while branched-chain amino acid pro-
duction, in this case by Prevotella copri and Bacteroides 
vulgatus, has previously been associated with metabolic 
dysfunction and future insulin resistance [47, 48].
The potential association of bile acid profile with dia-
betic state has been acknowledged for decades [49], 
yet the consequences of this interaction appear to have 
remained relatively underappreciated. In addition to the 
role of bile-mediated FXR signaling in correcting obesity, 
there are indications that this pathway may also impact 
insulin sensitivity [50]. A prospective study of diabetic 
women undergoing bariatric surgery identified a signifi-
cant increase in circulating FGF19 following the proce-
dure, which appeared to contribute to mitochondrial 
recovery and insulin sensitivity [51]. Moreover, targeted 
agonism of enterocyte FXR receptors with Fexaramine 
has previously been shown to trigger thermogenesis, adi-
pocyte browning and improved insulin sensitivity [52]. 
Indeed, there is indication now that FGF19 may acutely 
reduce circulating glucose levels through suppression of 
the hypothalamus–pituitary–adrenal axis [53].
Interestingly, TGR5 has been shown to modulate secre-
tion of the incretin GLP-1 [54], a gut hormone which 
has a range of beneficial systemic effects including satia-
tion, stimulation of insulin secretion and sensitivity, glu-
cogenesis and lipolysis [55]. Moreover, TGR5 has been 
implicated in the improved glucose homeostasis already 
attributed to bariatric surgery [56]. While GLP-1 has also 
been shown to have cardioprotective effects, in terms of 
inhibiting triglyceride-rich chylomicron formation [57, 
58], attenuation of atherogenic plaque inflammation [59] 
and modulation of cardiomyocyte function [60, 61], the 
importance of bile acid-mediated GLP-1 secretion in the 
context of CVD has not yet been fully explored. Until this 
point, we have discussed FXR and TGR5 bile signaling in 
isolation of each other; however, we now have clear evi-
dence that FXR also stimulates GLP-1 secretion through 
TGR5 upregulation, thereby ameliorating lipid metabo-
lism in mice [62].
Hepatic lipid metabolism
There is an established link between the composition 
and functionality of the gut microbiome and host lipid 
metabolism [63, 64]. A recent investigation into this rela-
tionship probed the 893-subject LifeLines-DEEP cohort 
dataset in an attempt to correlate microbial taxa relative 
abundances with metabolic markers such as BMI, choles-
terol and triglycerides [65]. The study reported a range 
of correlations, with the microbiome explaining  ~  5% 
of BMI, triglyceride and HDL-C variance independent 
of confounding factors, such as age, sex and genetic risk 
factors. Interestingly, of those most inversely correlated 
with BMI and circulating triglyceride levels were bile acid 
metabolizing taxa Bacteroidales and Clostridiaceae.
At the center of microbial bile metabolism are the BSH 
enzymes, which deconjugate bile salts, thereby render-
ing them exposed to numerous additional modifica-
tions. Joyce et  al. previously demonstrated the ability of 
a recombinant BSH-expressing microbe to substantially 
alter the host circulating bile acid profile and, in turn, 
markers of host lipid metabolism and circadian rhythm 
[66]. In support of this concept, a series of relatively 
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small clinical studies have demonstrated a role for BSH-
expressing microbes in the treatment of mildly hypercho-
lesterolaemic individuals. The bile-modifying microbe, 
Lactobacillus reuteri NCIMB 30242, has repeatedly 
been shown to modestly reduce circulating non-HDL-C 
levels, as well as other inflammatory markers of athero-
genesis [67, 68]. Furthermore, it has been reported that 
the BSH-active probiotic cocktail VSL#3, which has been 
demonstrated to induce bile acid synthesis through the 
aforementioned FXR-FGF15 axis [69], can beneficially 
alter serum cholesterol and the lipid profile of critically 
ill patients [70]. This same bile-modifying therapeutic has 
also been shown to significantly reduce the severity of 
non-alcoholic fatty liver disease (NAFLD) in obese chil-
dren [71].
From a clinical standpoint, clean receptor agonists/
antagonists would be more attractive than enzyme-
secreting microbes, in terms of ease of use, efficacy and 
safety. In line with this, several bile acid receptor ago-
nists/antagonists have been developed in recent years 
in an attempt to target this microbial–host crosstalk in 
certain metabolic pathologies [72]. FXR has been shown, 
through murine knock-out models, to play a central role 
in cholesterol homeostasis [73] and is therefore regarded 
as an important target for such putative therapeutics. At 
a molecular level, a downstream FXR-activated transla-
tional repressor of bile acid synthesis has been identified 
in mice as V-Maf avian musculoaponeurotic fibrosar-
coma oncogene homolog G [74]. In addition, the same 
group has also identified microRNA-144 as a key FXR-
mediated regulator of HDL-C metabolism through ATP 
binding cassette transporter A1 expression modulation 
[75], thus tying bile signaling neatly into the mammalian 
lipid metabolism system.
Obeticholic acid (OCA) is a highly potent semi-syn-
thetic derivative of the endogenous FXR-agonist cheno-
deoxycholic acid, which has demonstrated great promise 
in the treatment of a number of hepatic diseases [76]. 
The compound has now progressed through phase II and 
III clinical studies, effectively reducing several markers 
tightly associated with the liver failure that is observed 
in primary biliary cholangitis [77]. The utility of OCA 
was further strengthened by the successes of the FLINT 
cohort, a phase IIb NAFLD intervention study, in which 
the FXR agonist reduced all factors of the NAFLD activ-
ity score in concert [78]. However, despite the evident 
potential, no agonist studies targeting CVD outcomes 
have been reported in human subjects to date.
Vascular disease
Beyond lipid metabolism modulation, there is an emerg-
ing relationship between gut microbiome status and vas-
cular diseases, such as atherosclerosis, myocardial infarct 
and stroke [79, 80]. Moreover, there have been compel-
ling reports of associations between the oral microbiome 
and atherogenesis (reviewed extensively in [81]), while 
direct sequencing of atherosclerotic plaque microbial 
DNA itself has revealed a diverse ecosystem dominated 
predominantly by Proteobacteria [82–84]. Exploration of 
the gut microbiota in the Bogalusa Heart Study cohort 
previously demonstrated a link between life-time CVD-
risk and gene richness, as well as highlighting several spe-
cific diseases associated microbial taxa [85].
Beyond the modification of lipid risk factors, bile sign-
aling has been relatively underexplored as an immu-
nomodulatory pathway directly impacting upon vascular 
function. Despite this, bile acid receptors have been iden-
tified in the vasculature [86] and several bile acid receptor 
agonists have now demonstrated notable vascular effects 
in preclinical models, including promotion of reverse 
cholesterol transport [86, 87]. Two synthetic bile acid 
receptor ligands have also shown promise in the preven-
tion of atherogenesis. The first of which, WAY-362450, is 
a potent FXR agonist which was shown to dramatically 
reduce atherogenesis in two separate transgenic murine 
models of the disease state [88, 89]. Encouragingly, the 
FXR-agonist OCA has also shown promise in the pre-
vention of high-fat diet induced atherosclerosis, attenu-
ating plaque formation by 95% and several inflammatory 
markers associated with CVD progression in the apoli-
poprotein-E-deficient mouse model [90]. Finally, some 
intriguing in  vitro data are now available supporting a 
role for FXR-agonists in the prevention of the smooth 
muscle cell mediated atherogenic effects and migration 
processes [91], as well as downregulation of the vasocon-
strictor endothelin-1 [92].
Preclinical studies with the synthetic TGR5 agonist 
6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-
777) now also indicate a potential role of TGR5 in the 
prevention of atherosclerosis. The results demonstrated 
direct inhibition of NF-κB, which accompanied reduced 
lipid loading of macrophages and intraplaque inflamma-
tion [93]. In terms of natural ligands, taurolithocholic 
acid (TLCA) has also shown the potential to beneficially 
modulate vascular function in  vitro, significantly reduc-
ing tumor necrosis factor-α-induced monocyte infiltra-
tion, vascular cell adhesion protein-1 expression and 
activation of nuclear factor-κB, all through TGR5-medi-
ated pathways [94]. Taken together, these results indicate 
a potential immunomodulatory role for TGR5 agonists 
which should be further investigated for use in the clini-
cal context.
Hypertension and heart failure
The risk of CVD events in patients with concomitant 
hypertension is estimated to be raised by two to threefold 
Page 6 of 12Ryan et al. Diabetol Metab Syndr  (2017) 9:102 
[95]; therefore, elevated blood pressure represents a cen-
tral modifiable risk factor in prevention of the disease. 
Hypertension remission is a relatively common phenom-
enon associated with bariatric surgery and McGavigan 
and colleagues hypothesized that the alterations observed 
in microbiome composition and bile metabolism follow-
ing the procedure may have a role in this effect [96]. In 
this respect, it is interesting to note that FXR is expressed 
widely in vascular smooth muscle cells as well as in the 
heart, particularly the atrial myocardium [97]. In line 
with this, FXR agonist CDCA has been shown to reduce 
blood pressure in the spontaneous hypertensive rat 
model through iNOS expression [98]. Moreover, the FXR 
agonists PX20606 and OCA have exhibited the potential 
to partially reduce portal hypertension through modula-
tion of vascular tone [99, 100], a pathway which may have 
relevance for systemic hypertension.
From a wider CVD risk and heart failure-preserved 
ejection fraction (HF-PEF) perspective, there exists a 
clear relationship between hypertension, atrial struc-
tural change and atrial fibrillation. Given that altered 
serum bile acid composition is known to induce atrial 
arrhythmias in patients with atrial fibrillation [101], it is 
tempting to speculate that alteration in gut microbiome 
to enhance a “heart healthy” bile acid profile may have 
additional beneficial effects on hypertension-induced 
changes to atrial structure. Nonetheless, despite several 
intriguing conference abstracts purporting a down-regu-
lation of FXR expression in the left ventricle of sponta-
neous hypertensive rats with end-stage heart failure [102, 
103], formally published confirmatory evidence has yet to 
surface.
Caveats of bile acid research
Animal models
When considering microbiome effects on bile acid sign-
aling it is noteworthy that physiological differences and 
inconsistencies exist between animal models and the 
human system. While the gut microbiome can appear 
relatively similar between rodents and humans at the 
level of phylum, further probing to the genus level reveals 
a juxtaposition in the proportions of several bacterial 
taxa considered of importance to host health and disease 
[104]. Diet is a powerful regulator of the intestinal micro-
biome and is therefore an essential consideration when 
comparing herbivorous rodents to omnivorous humans. 
Nevertheless, the scientific community now has access to 
numerous validated and stable murine [105] and porcine 
[106] models of the ‘humanized’ gut microbiome, as well 
as animal diets which effectively mimic the macro- and 
micronutrient composition of our own.
A further consideration, which is highly pertinent 
to this review, is the differences in serum bile pro-
files between rodents and humans [107]. Most notably, 
rodent hepatocytes uniquely express a cytochrome P450 
enzyme, CYP2C9, which catalyses the hydroxylation of 
CDCA and UDCA to α-muricholic acid and β-muricholic 
acid, respectively [108]. In addition, the proportion of cir-
culating tauro-conjugated bile acids vastly outweighs the 
glycol-conjugated bile acids in the rodent system, while 
the reverse is true in the human circulation [107]. These 
are significant divergences in biochemistry and would 
undoubtedly impact upon the extrapolation of conclu-
sions drawn from animal models. However, the use of 
porcine models, which more closely mirror the circulat-
ing bile acid profile and general physiology of humans 
[109, 110], may be sufficient in this regard.
Tissue specificity
Despite the outlined successes of several FXR mediated 
therapeutics, significant disparities in the downstream 
actions of FXR signaling have been observed [111]. 
Indeed, while some studies report correction of lipid 
profile [112], an equal number of studies demonstrate 
the involvement of FXR in dyslipidaemia [113]. How-
ever, a number of useful conclusions can be drawn from 
FXR knock-out mouse models to date. Firstly, much of 
the reported inconsistency between studies appears to 
be related to the notably high degree of tissue speci-
ficity of FXR. For example, Schmitt et  al. previously 
demonstrated that hepatic FXR expression was protec-
tive against hepatic lipid accumulation, while intestinal 
expression and subsequent FGF15 signaling conferred 
no such effect [114]. A molecular basis for these tissue 
specific effects has now been proposed [115]. It has been 
observed in mice that intestinal FXR-mediated FGF15 
signaling reduced hepatic expression of CYP7A1, the 
rate limiting enzyme of the classic bile acid synthesis 
pathway, while liver FXR activation primarily repressed 
hepatic CYP8B1, which is responsible for CA synthesis 
[115]. This seemingly minute discrepancy likely plays 
a significant role in the inconsistencies in outcomes 
observed between murine studies. Indeed, a series of 
subsequent agonistic experiments have supported the 
hypothesis that FXR activation within an ileal entero-
cyte [52, 116] can have vastly contrasting effects to that 
of hepatocyte stimulation [113, 117]. Therefore, we 
must acknowledge and continue to examine closely the 
juxtaposed physiological responses which can be gen-
erated in some cases from the same signal, and design 
such drugs carefully with their desired pharmacokinet-
ics in mind.
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Translational outlook
Over the past several decades, a multiplicity of clinically 
relevant functions of the microbiome have become evi-
dent including inter alia prevention of enteral coloniza-
tion by pathogens, education of the host immune system, 
modulation of host metabolism, bile acid deconjugation 
and caloric salvage, production of essential short chain 
fatty acids, vitamin B and K synthesis and even participa-
tion in cardiac drug metabolism [118, 119]. Associations 
between gut microbiome profiles and host cardiometa-
bolic health are tantalizing in preclinical models but 
remain to be demonstrated as causal in man. Thus, we 
stand on the cusp of translation of this preclinical knowl-
edge to clinical practice [45, 120–122].
Intriguingly, microbiome research is now presenting 
new insights into the multifactorial mechanisms through 
which cardiometabolic pathologies arise and in doing 
so presents exciting prospects for development of novel 
therapeutics and targets within human subjects. These 
therapies span the spectrum of prebiotic [123], tradi-
tional and next generation probiotics to biotherapeu-
tic compounds whole or in part derived from microbes. 
Therapeutic strategies can vary from selecting probiotic 
strains associated with cardiovascular health or alterna-
tively using well described strains as vehicles to deliver 
molecules or compounds associated with disease miti-
gation. For instance, seminal studies on the relationship 
between diet, gut microbiome and TMAO suggest new 
therapeutic targets for atherosclerosis that are gut micro-
biome based [7, 8, 124, 125].
Moreover, while statin-based therapies represent the 
gold standard and have proven highly effective in the 
management of LDL-C and CVD risk, there remain a 
subset of at-risk hyperlipidemic patients who are par-
tially or entirely intolerant of this drug class. Therefore, 
there remains scope for in silico mining and develop-
ment of novel microbial-derived molecular targets [126], 
or even the exploitation of whole bacterial therapies as 
adjuncts to standard management regimes [67, 68, 70, 
127]. Indeed, although recent clinical trials indicate that 
LDLR-promoting proprotein convertase subtilisin/kexin 
type 9-inhibitor injections are safe and highly potent in 
circulating LDL-C reduction [128], such antibody-based 
therapies are inordinately expensive for much of the gen-
eral population and thus cost-effective adjunctive thera-
pies that are microbiome-based may add incremental 
benefit in this clinical space.
Already, a number of human studies have indicated 
promising correlations and direct effects of specific 
microbial taxa on weight loss, glucose metabolism and 
correction of other phenotypes of metabolic syndrome 
[122, 129–132]. Additional future microbiome targets 
may include regulation of vascular tone, hypertension, 
diastolic dysfunction, insulin resistance, circadian 
rhythm, satiety and obesity through alterations in bile 
salt and short chain fatty acid metabolism [133]. How-
ever, it is important to address one caveat within the 
field of microbiome research: the overwhelming majority 
of data available are cataloguing of microbial taxa from 
faeces and their association with host cardiometabolic 
phenotypes. This essentially represents descriptive phe-
nomenology, which, unfortunately, does not often lead to 
actionable mechanistic understandings. We now require 
neatly-designed longitudinal and prospective interven-
tional clinical studies [134], coupled with thoroughly-
considered reductionist studies utilizing both germ free 
and environmentally enriched pre-clinical models with 
gain/loss of function of specific genetic pathways. These 
definitive mechanistic studies will act as a prelude to 
expansion of microbiome therapeutics to the wider clini-
cal community of cardiovascular disease and metabolic 
syndrome patients.
Although the promise of the personalized medicine 
predicted upon completion of the Human Genome 
Project [135] has not yet been fulfilled [136, 137], evi-
dence presented in this review indicates a new and likely 
equally important host bacterial genome for clinicians 
to consider, if the design of future personalized thera-
peutic interventions are to be most effective. Due to the 
individuality of our intestinal bacteria, some studies have 
already encountered complex multifactorial and person-
alized interactions between interventions and the gut 
microbiome, ultimately stratifying patients into respond-
ers and non-responders for some widely prescribed drug 
classes [138, 139]. As a more integrative understanding of 
microbiome composition and functionality is obtained, it 
may even become possible to apply a model not unlike 
the thrombosis and myocardial infarction (TIMI) score 
[140], which can broadly assess the likelihood of whether 
a microbiome composition is contributing to cardiomet-
abolic dysfunction risk by stratifying certain microbial 
taxa as positively and negatively associated with such a 
disease state. Indeed, such a tool could make it possible 
to identify taxa or cohorts of taxa that should be reintro-
duced to the patient microbiome, in an attempt to rectify 
functional metabolic imbalances. This has already been 
elegantly demonstrated with respect to health, frailty and 
predisposition to disease in the elderly [120].
Finally, we must continue to recognize the power of 
diet and lifestyle adjustments in augmenting a patient’s 
disease risk status. In line with this, clinical evidence that 
implicates diet [141] and exercise [142, 143] as potent 
factors in beneficially modulating the composition and 
functionality of our gut microbiome is now emerging. 
Most recently, a meta-analysis of twenty randomized 
controlled trials found that intervention with inulin-type 
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fructan fibres confers a reduction of circulating LDL-C in 
all subjects, while also reducing fasting insulin levels in 
type-2 diabetic patients [144]. Indeed, dietary ingredients 
are currently leading candidates in the translational pipe-
line and perhaps represent the most realistic means of 
manipulating the gut microbiome for beneficial augmen-
tation of cardiometabolic resilience.
Conclusions
The gut microbiome represents the physiological ‘system’ 
which is perhaps most readily modified by external factors, 
such as diet [141, 145] and pharmacologic applications 
[146]. Current knowledge implicates reduced bacterial 
diversity and in turn, reduced gene richness and metabolic 
capacity within the gut microbiome as a driving factor of 
metabolic dysfunction and the collapse of host systemic 
homeostasis. In this review, we have evinced a unity in 
several of these functional aspects of the microbiome, in 
the context of cardiometabolic health. In this respect, bile 
acids have now emerged as one of the central tenets of 
microbe–host crosstalk, with the potential to impact on 
many aspects of host cardiometabolic health, including 
those involved in CVD pathology. While immune interac-
tions are clearly central to the microbiome–host interac-
tion, it is evident that enteric microbes have the potential 
to produce scores of different bile acid derivatives from 
deconjugation and dehydoxylation processes. This sug-
gests that bile acids potentially may represent an entire 
language, rather than a simple signal in this crosstalk. It is 
clear that we are still a distance away from comprehending 
the true complexities and subtleties involved in bile pool 
composition, receptor tissue specificity and nuclear recep-
tor promiscuity, but these pathways may hold the key to 
many previously unexplained microbiome–host health 
associations and correlations, and are therefore inherently 
intriguing in respect of cardiovascular health.
Authors’ contributions
PMR and NMC drafted the manuscript, while NMC and CS reviewed and final-
ized it. All authors read and approved the final manuscript.
Author details
1 APC Microbiome Institute, Biosciences Institute, University College Cork, 
Cork, Ireland. 2 Centre for Research in Vascular Biology, University College Cork, 
Co. Cork, Ireland. 3 Food Biosciences Department, Teagasc Food Research 
Centre, Moorepark, Fermoy, Co. Cork, Ireland. 
Acknowledgements
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Not applicable.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
This work is supported in part by the APC Microbiome Institute (under Science 
Foundation Ireland [SFI] Grant Number: SFI/12/RC/2273) and by Enterprise 
Ireland Commercialization Fund (Contract Reference: CF/2013/3030A/B).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 26 September 2017   Accepted: 7 December 2017
References
 1. Sender R, Fuchs S, Milo R. Revised estimates for the number of human 
and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533.
 2. Derrien M, van Hylckama Vlieg JE. Fate, activity, and impact of 
ingested bacteria within the human gut microbiota. Trends Microbiol. 
2015;23(6):354–66.
 3. Fontana L, Partridge L. Promoting health and longevity through diet: 
from model organisms to humans. Cell. 2015;161(1):106–18.
 4. Moeller AH, Li Y, Ngole EM, Ahuka-Mundeke S, Lonsdorf EV, Pusey AE, 
Peeters M, Hahn BH, Ochman H. Rapid changes in the gut microbiome 
during human evolution. Proc Natl Acad Sci. 2014;111(46):16431–5.
 5. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, 
Wu Y, Li L, et al. Intestinal microbiota metabolism of l-carnitine, a nutri-
ent in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.
 6. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. 
Intestinal microbial metabolism of phosphatidylcholine and cardiovas-
cular risk. N Engl J Med. 2013;368(17):1575–84.
 7. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, 
Zamanian-Daryoush M, Culley Miranda K, et al. Non-lethal inhibition of 
gut microbial trimethylamine production for the treatment of athero-
sclerosis. Cell. 2015;163(7):1585–95.
 8. Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown 
AL, Marshall S, McDaniel A, Schugar RC, Wang Z, et al. The TMAO-
generating enzyme flavin monooxygenase 3 is a central regulator of 
cholesterol balance. Cell Rep. 2015;10(3):326–38.
 9. Meyer K, Shea J. Dietary choline and betaine and risk of CVD: a 
systematic review and meta-analysis of prospective studies. Nutrients. 
2017;9(7):711.
 10. Jones BV, Begley M, Hill C, Gahan CGM, Marchesi JR. Functional and 
comparative metagenomic analysis of bile salt hydrolase activity in the 
human gut microbiome. Proc Natl Acad Sci. 2008;105(36):13580–5.
 11. Stellwag EJ, Hylemon PB. 7alpha-Dehydroxylation of cholic acid 
and chenodeoxycholic acid by Clostridium leptum. J Lipid Res. 
1979;20(3):325–33.
 12. Martin FPJ, Dumas ME, Wang Y, Legido-Quigley C, Yap IKS, Tang H, Zirah 
S, Murphy GM, Cloarec O, Lindon JC, et al. A top-down systems biology 
view of microbiome–mammalian metabolic interactions in a mouse 
model. Mol Syst Biol. 2007;112:1–16.
 13. Lee J-Y, Arai H, Nakamura Y, Fukiya S, Wada M, Yokota A. Contribution 
of the 7β-hydroxysteroid dehydrogenase from Ruminococcus gnavus 
N53 to ursodeoxycholic acid formation in the human colon. J Lipid Res. 
2013;54(11):3062–9.
 14. Ridlon JM, Kang D-J, Hylemon PB. Isolation and characterization of 
a bile acid inducible 7α-dehydroxylating operon in Clostridium hyl-
emonae TN271. Anaerobe. 2010;16(2):137–46.
 15. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, 
Nicholson JK, Holmes E. Systemic gut microbial modulation of bile 
acid metabolism in host tissue compartments. Proc Natl Acad Sci USA. 
2011;1:4523–30.
 16. Aron-Wisnewsky J, Clement K. The gut microbiome, diet, and 
links to cardiometabolic and chronic disorders. Nat Rev Nephrol. 
2016;12(3):169–81.
Page 9 of 12Ryan et al. Diabetol Metab Syndr  (2017) 9:102 
 17. Joyce SA, Gahan CG. Bile acid modifications at the microbe–host 
interface: potential for nutraceutical and pharmaceutical interventions 
in host health. Annu Rev Food Sci Technol. 2016;7:313–33.
 18. Govindarajan K, MacSharry J, Casey PG, Shanahan F, Joyce SA, Gahan 
CGM. Unconjugated bile acids influence expression of circadian 
genes: a potential mechanism for microbe–host crosstalk. PLoS ONE. 
2016;11(12):e0167319.
 19. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, 
Hill C, Gahan CGM. Regulation of host weight gain and lipid metabo-
lism by bacterial bile acid modification in the gut. Proc Natl Acad Sci. 
2014;111(20):7421–6.
 20. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, Kim SG, 
Li H, Gao Z, Mahana D, et al. Altering the intestinal microbiota during 
a critical developmental window has lasting metabolic consequences. 
Cell. 2014;158(4):705–21.
 21. Korpela K, Zijlmans MAC, Kuitunen M, Kukkonen K, Savilahti E, Salonen 
A, de Weerth C, de Vos WM. Childhood BMI in relation to microbiota in 
infancy and lifetime antibiotic use. Microbiome. 2017;5(1):26.
 22. Azad MB, Bridgman SL, Becker AB, Kozyrskyj AL. Infant antibiotic 
exposure and the development of childhood overweight and central 
adiposity. Int J Obes. 2014;38:1290–8.
 23. Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. 
Association of antibiotics in infancy with early childhood obesity. JAMA 
Pediatr. 2014;168:1063–9.
 24. Bergstrom A, Skov TH, Bahl MI, Roager HM, Christensen LB, Ejlerskov KT, 
Molgaard C, Michaelsen KF, Licht TR. Establishment of intestinal micro-
biota during early life: a longitudinal, explorative study of a large cohort 
of Danish infants. Appl Environ Microbiol. 2014;80:2889–900.
 25. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, 
Almeida M, Arumugam M, Batto J-M, Kennedy S, et al. Richness of 
human gut microbiome correlates with metabolic markers. Nature. 
2013;500(7464):541–6.
 26. Medina DA, Pedreros JP, Turiel D, Quezada N, Pimentel F, Escalona A, 
Garrido D. Distinct patterns in the gut microbiota after surgical or medi-
cal therapy in obese patients. PeerJ. 2017;5:e3443.
 27. Shimizu H, Hatao F, Imamura K, Takanishi K, Tsujino M. Early effects of 
sleeve gastrectomy on obesity-related cytokines and bile acid metabo-
lism in morbidly obese Japanese patients. Obes Surg. 2017;12:3223–29.
 28. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, 
Myronovych A, Karns R, Wilson-Perez HE, Sandoval DA, Kohli R, Backhed 
F, et al. FXR is a molecular target for the effects of vertical sleeve gas-
trectomy. Nature. 2014;509(7499):183–8.
 29. Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ. 
Fibroblast growth factor-19 action in the brain reduces food intake and 
body weight and improves glucose tolerance in male rats. Endocrinol-
ogy. 2013;154(1):9–15.
 30. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted 
disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid 
homeostasis. Cell. 2000;102(6):731–44.
 31. Wahlstrom A, Sayin SI, Marschall HU, Backhed F. Intestinal crosstalk 
between bile acids and microbiota and its impact on host metabolism. 
Cell Metab. 2016;24(1):41–50.
 32. Zhang L, Xie C, Nichols RG, Chan SHJ, Jiang C, Hao R, Smith PB, Cai J, 
Simons MN, Hatzakis E, et al. Farnesoid X receptor signaling shapes 
the gut microbiota and controls hepatic lipid metabolism. mSystems. 
2016;1(5):e00070-16.
 33. Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Pat-
terson AD, Gonzalez FJ. Microbiome remodelling leads to inhibition of 
intestinal farnesoid X receptor signalling and decreased obesity. Nat 
Commun. 2013;4:2384.
 34. Parséus A, Sommer N, Sommer F, Caesar R, Molinaro A, Ståhlman M, 
Greiner TU, Perkins R, Bäckhed F. Microbiota-induced obesity requires 
farnesoid X receptor. Gut. 2017;66(3):429–37.
 35. Shimizu H, Hatao F, Imamura K, Takanishi K, Tsujino M. Early effects 
of sleeve gastrectomy on obesity-related cytokines and bile acid 
metabolism in morbidly obese Japanese patients. Obes Surg. 
2017;31(10):017–2756.
 36. Risstad H, Kristinsson JA, Fagerland MW, le Roux CW, Birkeland KI, 
Gulseth HL, Thorsby PM, Vincent RP, Engström M, Olbers T, et al. 
Bile acid profiles over 5 years after gastric bypass and duodenal 
switch: results from a randomized clinical trial. Surg Obes Relat Dis. 
2017;13(9):1544–53.
 37. Belgaumkar AP, Vincent RP, Carswell KA, Hughes RD, Alaghband-Zadeh 
J, Mitry RR, le Roux CW, Patel AG. Changes in bile acid profile after lapa-
roscopic sleeve gastrectomy are associated with improvements in met-
abolic profile and fatty liver disease. Obes Surg. 2016;26(6):1195–202.
 38. Sayin Sama I, Wahlström A, Felin J, Jäntti S, Marschall H-U, Bamberg 
K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut microbiota 
regulates bile acid metabolism by reducing the levels of tauro-beta-
muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 
2013;17(2):225–35.
 39. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato 
H, Messaddeq N, Harney JW, Ezaki O, Kodama T, et al. Bile acids induce 
energy expenditure by promoting intracellular thyroid hormone activa-
tion. Nature. 2006;439(7075):484–9.
 40. Broeders EP, Nascimento EB, Havekes B, Brans B, Roumans KH, Tailleux 
A, Schaart G, Kouach M, Charton J, Deprez B, et al. The bile acid cheno-
deoxycholic acid increases human brown adipose tissue activity. Cell 
Metab. 2015;22(3):418–26.
 41. Stanford KI, Middelbeek RJW, Townsend KL, An D, Nygaard EB, Hitchcox 
KM, Markan KR, Nakano K, Hirshman MF, Tseng Y-H, et al. Brown adipose 
tissue regulates glucose homeostasis and insulin sensitivity. J Clin Inves-
tig. 2013;123(1):215–23.
 42. Long J, Cai Q, Steinwandel M, Hargreaves MK, Bordenstein SR, Blot WJ, 
Zheng W, Shu XO. Association of oral microbiome with type 2 diabetes 
risk. J Periodontal Res. 2017;52(3):636–43.
 43. Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L. Human gut 
microbiota changes reveal the progression of glucose intolerance. PLoS 
ONE. 2013;8(8):e71108.
 44. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fager-
berg B, Nielsen J, Backhed F. Gut metagenome in European women 
with normal, impaired and diabetic glucose control. Nature. 
2013;498(7452):99–103.
 45. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, 
Jensen BAH, Forslund K, Hildebrand F, Prifti E, Falony G, et al. Human 
gut microbes impact host serum metabolome and insulin sensitivity. 
Nature. 2016;535(7612):376–81.
 46. De Vadder F, Kovatcheva-Datchary P, Zitoun C, Duchampt A, Bäckhed F, 
Mithieux G. Microbiota-produced succinate improves glucose homeo-
stasis via intestinal gluconeogenesis. Cell Metab. 2016;24(1):151–7.
 47. Würtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M, 
Viikari JS, Raitakari OT, Ala-Korpela M. Branched-chain and aromatic 
amino acids are predictors of insulin resistance in young adults. Diabe-
tes Care. 2013;36(3):648–55.
 48. McCormack SE, Shaham O, McCarthy MA, Deik AA, Wang TJ, Gerszten 
RE, Clish CB, Mootha VK, Grinspoon SK, Fleischman A. Circulating 
branched-chain amino acid concentrations are associated with obesity 
and future insulin resistance in children and adolescents. Pediatr Obes. 
2013;8(1):52–61.
 49. Ogura Y, Ito T, Ogura M. Effect of diabetes and of 7 alpha-hydroxycho-
lesterol infusion on the profile of bile acids secreted by the isolated rat 
livers. Biol Chem Hoppe Seyler. 1986;367(10):1095–9.
 50. Kreznar JH, Keller MP, Traeger LL, Rabaglia ME, Schueler KL, Stapleton 
DS, Zhao W, Vivas EI, Yandell BS, Broman AT, et al. Host genotype and 
gut microbiome modulate insulin secretion and diet-induced meta-
bolic phenotypes. Cell Rep. 2017;18(7):1739–50.
 51. de la Escalera LM, Kyrou I, Vrbikova J, Hainer V, Sramkova P, Fried M, Piya 
MK, Kumar S, Tripathi G, McTernan PG. Impact of gut hormone FGF-19 
on type-2 diabetes and mitochondrial recovery in a prospective study 
of obese diabetic women undergoing bariatric surgery. BMC Med. 
2017;15(1):34.
 52. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino 
A, Jacinto S, Lukasheva Y, et al. Intestinal FXR agonism promotes adi-
pose tissue browning and reduces obesity and insulin resistance. Nat 
Med. 2015;21(2):159–65.
 53. Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI. FGF1 and 
FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–
adrenal axis. Nat Commun. 2015;6:6980.
 54. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like 
peptide-1 secretion through TGR5 in a murine enteroendocrine cell line 
STC-1. Biochem Biophys Res Commun. 2005;329(1):386–90.
Page 10 of 12Ryan et al. Diabetol Metab Syndr  (2017) 9:102 
 55. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell 
Metab. 2016;24(1):15–30.
 56. McGavigan AK, Garibay D, Henseler ZM, Chen J, Bettaieb A, Haj FG, Ley 
RE, Chouinard ML, Cummings BP. TGR5 contributes to glucoregula-
tory improvements after vertical sleeve gastrectomy in mice. Gut. 
2017;66(2):226–34.
 57. Xiao C, Dash S, Morgantini C, Lewis GF. New and emerging regulators of 
intestinal lipoprotein secretion. Atherosclerosis. 2014;233(2):608–15.
 58. Xiao C, Dash S, Morgantini C, Patterson BW, Lewis GF. Sitagliptin, a 
DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion 
in healthy humans. Diabetes. 2014;63(7):2394–401.
 59. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani 
Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhe-
sion to endothelial cells and attenuation of atherosclerotic lesion 
by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 
2010;59(4):1030–7.
 60. Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, 
Baranek BM, Stoffers DA, Seeley RJ, et al. Inactivation of the cardiomyo-
cyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomy-
ocyte-independent GLP-1R-mediated cardioprotection. Mol Metab. 
2014;3(5):507–17.
 61. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simp-
son JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial 
natriuretic peptide secretion to control of blood pressure. Nat Med. 
2013;19(5):567–75.
 62. Pathak P, Liu H, Boehme S, Xie C, Krausz KW, Gonzalez F, Chiang JYL. 
Farnesoid X receptor induces Takeda G-protein receptor 5 crosstalk 
to regulate bile acid synthesis and hepatic metabolism. J Biol Chem. 
2017;292(26):11055–69.
 63. Caesar R, Nygren H, Orešič M, Bäckhed F. Interaction between dietary 
lipids and gut microbiota regulates hepatic cholesterol metabolism. J 
Lipid Res. 2016;57(3):474–81.
 64. Mistry RH, Verkade HJ, Tietge UJF. Reverse cholesterol transport 
is increased in germ-free mice. Arterioscler Thromb Vasc Biol. 
2017;37(3):419–22.
 65. Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JAM, 
Brandsma E, Marczynska J, Imhann F, Weersma RK, et al. The gut micro-
biome contributes to a substantial proportion of the variation in blood 
lipids. Circ Res. 2015;117(9):817–24.
 66. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, 
Hill C, Gahan CG. Regulation of host weight gain and lipid metabolism 
by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA. 
2014;111:7421–6.
 67. Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of 
sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized 
controlled trial. Eur J Clin Nutr. 2012;66(11):1234–41.
 68. Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy 
of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri 
NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J 
Nutr. 2012;107(10):1505–13.
 69. Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota 
modification with probiotics induces hepatic bile acid synthesis via 
downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014;7(1):12–8.
 70. Sanaie S, Ebrahimi-Mameghani M, Mahmoodpoor A, Shadvar K, 
Golzari SE. Effect of a probiotic preparation (VSL#3) on cardiovascu-
lar risk parameters in critically-ill patients. J Cardiovasc Thorac Res. 
2013;5(2):67–70.
 71. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, 
Reali L, Anania F, Nobili V. Randomised clinical trial: the beneficial effects 
of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment 
Pharmacol Ther. 2014;39(11):1276–85.
 72. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Target-
ing bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 
2008;7(8):678–93.
 73. Lambert G, Amar MJA, Guo G, Brewer HB, Gonzalez FJ, Sinal CJ. The 
farnesoid X-receptor is an essential regulator of cholesterol homeosta-
sis. J Biol Chem. 2003;278(4):2563–70.
 74. de Aguiar Vallim TQ, Tarling EJ, Ahn H, Hagey LR, Romanoski CE, Lee RG, 
Graham MJ, Motohashi H, Yamamoto M, Edwards PA. MAFG is a tran-
scriptional repressor of bile acid synthesis and metabolism. Cell Metab. 
2015;21(2):298–310.
 75. de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldán Á, Esau C, 
Edwards PA. MicroRNA-144 regulates hepatic ATP binding cas-
sette transporter A1 and plasma high-density lipoprotein after 
activation of the nuclear receptor farnesoid X receptor. Circ Res. 
2013;112(12):1602–12.
 76. Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst 
I, Windmolders P, Farre R, Wenes M, Mazzone M, et al. FXR agonist obet-
icholic acid reduces hepatic inflammation and fibrosis in a rat model of 
toxic cirrhosis. Sci Rep. 2016;6:33453.
 77. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, 
Kowdley KV, Vincent C, Bodhenheimer HC Jr, Pares A, et al. Efficacy 
of obeticholic acid in patients with primary biliary cirrhosis and 
inadequate response to ursodeoxycholic acid. Gastroenterology. 
2015;148(4):751.e758–761.e758.
 78. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, 
Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, et al. 
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, 
non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, 
placebo-controlled trial. Lancet. 2015;385(9972):956–65.
 79. Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, Gross GJ, Salzman 
NH, Baker JE. Intestinal microbiota determine severity of myocardial 
infarction in rats. FASEB J. 2012;26(4):1727–35.
 80. Lam V, Su J, Hsu A, Gross GJ, Salzman NH, Baker JE. Intestinal microbial 
metabolites are linked to severity of myocardial infarction in rats. PLoS 
ONE. 2016;11(8):e0160840.
 81. Chhibber-Goel J, Singhal V, Bhowmik D, Vivek R, Parakh N, Bhargava B, 
Sharma A. Linkages between oral commensal bacteria and atheroscle-
rotic plaques in coronary artery disease patients. npj Biofilms Microbi-
omes. 2016;2(1):7.
 82. Mitra S, Drautz-Moses DI, Alhede M, Maw MT, Liu Y, Purbojati RW, Yap 
ZH, Kushwaha KK, Gheorghe AG, Bjarnsholt T, et al. In silico analyses of 
metagenomes from human atherosclerotic plaque samples. Microbi-
ome. 2015;3(1):38.
 83. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, Behre CJ, 
Knight R, Fagerberg B, Ley RE, et al. Human oral, gut, and plaque 
microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA. 
2011;108(Suppl 1):4592–8.
 84. Ziganshina EE, Sharifullina DM, Lozhkin AP, Khayrullin RN, Ignatyev 
IM, Ziganshin AM. Bacterial communities associated with atheroscle-
rotic plaques from russian individuals with atherosclerosis. PLoS ONE. 
2016;11(10):e0164836.
 85. Kelly TN, Bazzano LA, Ajami NJ, He H, Zhao J, Petrosino JF, Correa 
A, He J. Gut microbiome associates with lifetime cardiovascular 
disease risk profile among Bogalusa heart study participants. Circ Res. 
2016;119(8):956–64.
 86. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of 
the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA. 
2004;101(10):3668–73.
 87. Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, Willson TM, Edwards PA. 
Identification of novel pathways that control farnesoid X receptor-
mediated hypocholesterolemia. J Biol Chem. 2010;285(5):3035–43.
 88. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Acti-
vation of farnesoid X receptor prevents atherosclerotic lesion formation 
in  LDLR−/− and  apoE−/− mice. J Lipid Res. 2009;50(6):1090–100.
 89. Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, Foster P, Li J, 
Pircher P, Petrowski M, et al. Discovery of XL335 (WAY-362450), a highly 
potent, selective, and orally active agonist of the farnesoid X receptor 
(FXR). J Med Chem. 2009;52(4):904–7.
 90. Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic 
effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 
2009;296(2):H272–81.
 91. Li YTY, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D. Farnesoid X 
receptor ligands inhibit vascular smooth muscle cell inflammation and 
migration. Arterioscler Thromb Vasc Biol. 2007;27(12):2606–11.
 92. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Wat-
kins S, et al. Downregulation of endothelin-1 by farnesoid X receptor in 
vascular endothelial cells. Circ Res. 2006;98(2):192–9.
 93. Thijs TWH, Nomura M, Harach T, Lo Sasso G, Oosterveer Maaike H, 
Thomas C, Rizzo G, Gioiello A, Adorini L, Pellicciari R, et al. TGR5 activa-
tion inhibits atherosclerosis by reducing macrophage inflammation 
and lipid loading. Cell Metab. 2011;14(6):747–57.
Page 11 of 12Ryan et al. Diabetol Metab Syndr  (2017) 9:102 
 94. Kida T, Tsubosaka Y, Hori M, Ozaki H, Murata T. Bile acid receptor 
TGR5 agonism induces NO production and reduces monocyte 
adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 
2013;33(7):1663–9.
 95. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention 
and treatment. JAMA. 1996;275(20):1571–6.
 96. McGavigan AK, Henseler ZM, Garibay D, Butler SD, Jayasinghe S, Ley RE, 
Davisson RL, Cummings BP. Vertical sleeve gastrectomy reduces blood 
pressure and hypothalamic endoplasmic reticulum stress in mice. Dis 
Models Mech. 2017;10(3):235–43.
 97. Salpeas V, Tsoporis J, Izhar S, Sakadakis E, Rigopoulos AG, Parker TG, 
Rizos IK. Abstract 15690: statins as potential farnesoid X receptor modu-
lators in atrial cardiomyocytes: a gender, age and miR328 controlled 
response. Circulation. 2014;130(Suppl 2):A15690.
 98. Li C, Li J, Weng X, Lan X, Chi X. Farnesoid X receptor agonist CDCA 
reduces blood pressure and regulates vascular tone in spontaneously 
hypertensive rats. J Am Soc Hypertens. 2015;9(7):507.e507–516.e507.
 99. Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, 
Strobel B, Schubert T-L, Riedl F, Mitteregger D, et al. The FXR agonist 
PX20606 ameliorates portal hypertension by targeting vascular remod-
elling and sinusoidal dysfunction. J Hepatol. 2017;66(4):724–33.
 100. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, 
Windmolders P, Vanuytsel T, Nevens F, et al. Obeticholic acid, a farnesoid 
X receptor agonist, improves portal hypertension by two distinct path-
ways in cirrhotic rats. Hepatology. 2014;59(6):2286–98.
 101. Rainer PP, Primessnig U, Harenkamp S, Doleschal B, Wallner M, Fauler 
G, Stojakovic T, Wachter R, Yates A, Groschner K, et al. Bile acids induce 
arrhythmias in human atrial myocardium—implications for altered 
serum bile acid composition in patients with atrial fibrillation. Heart. 
2013;99(22):1685–92.
 102. Salpeas V, Rizos I, Rigopoulos A, Sakadakis E, Villaras G, Rallidis L, Kre-
mastinos D, Patsouris E. FXR nuclear receptor down-regulation in left 
ventricle of aging SHR: a possible end-stage heart failure bioenergetics 
adjustment. J Mol Cell Cardiol. 2008;44(4):821.
 103. Salpeas V, Rizos GA, Rigopoulos A, Sakadakis E, Kremastinos D, Patsouris 
E. 532 down-regulation of fxr nuclear receptor in left ventricle of aging 
shr: a possible end-stage heart failure bioenergetics adjustment. Eur 
Journal Heart Fail Suppl. 2008;7:136–7.
 104. Nguyen TLA, Vieira-Silva S, Liston A, Raes J. How informative is the 
mouse for human gut microbiota research? Dis Models Mech. 
2015;8(1):1–16.
 105. Staley C, Kaiser T, Beura LK, Hamilton MJ, Weingarden AR, Bobr A, Kang 
J, Masopust D, Sadowsky MJ, Khoruts A. Stable engraftment of human 
microbiota into mice with a single oral gavage following antibiotic 
conditioning. Microbiome. 2017;5(1):87.
 106. Zhang Q, Widmer G, Tzipori S. A pig model of the human gastrointesti-
nal tract. Gut Microbes. 2013;4(3):193–200.
 107. García-Cañaveras JC, Donato MT, Castell JV, Lahoz A. Targeted profiling 
of circulating and hepatic bile acids in human, mouse, and rat using a 
UPLC-MRM-MS-validated method. J Lipid Res. 2012;53(10):2231–41.
 108. Takahashi S, Fukami T, Masuo Y, Brocker CN, Xie C, Krausz KW, Wolf CR, 
Henderson CJ, Gonzalez FJ. Cyp2c70 is responsible for the species dif-
ference in bile acid metabolism between mice and humans. J Lipid Res. 
2016;57(12):2130–7.
 109. Kobayashi E, Hishikawa S, Teratani T, Lefor AT. The pig as a model for 
translational research: overview of porcine animal models at Jichi Medi-
cal University. Transplant Res. 2012;1(1):8.
 110. Swindle MM, Makin A, Herron AJ, Clubb FJ Jr, Frazier KS. Swine as 
models in biomedical research and toxicology testing. Vet Pathol. 
2012;49(2):344–56.
 111. Gonzalez FJ, Jiang C, Xie C, Patterson AD. Intestinal farnesoid X receptor 
signaling modulates metabolic disease. Dig Dis. 2017;35(3):178–84.
 112. Amano Y, Shimada M, Miura S, Adachi R, Tozawa R. Antidyslipidemic 
effects of a farnesoid X receptor antagonist in primates. Life Sci. 
2014;106(1–2):25–31.
 113. Pencek R, Marmon T, Roth JD, Liberman A, Hooshmand-Rad R, Young 
MA. Effects of obeticholic acid on lipoprotein metabolism in healthy 
volunteers. Diabetes Obes Metab. 2016;18(9):936–40. https://doi.
org/10.1111/dom.12681 (Epub 2016 Jun 6).
 114. Schmitt J, Kong B, Stieger B, Tschopp O, Schultze SM, Rau M, Weber A, 
Mullhaupt B, Guo GL, Geier A. Protective effects of farnesoid X receptor 
(FXR) on hepatic lipid accumulation are mediated by hepatic FXR and 
independent of intestinal FGF15 signal. Liver Int. 2015;35(4):1133–44.
 115. Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez 
FJ. Differential regulation of bile acid homeostasis by the farnesoid X 
receptor in liver and intestine. J Lipid Res. 2007;48(12):2664–72.
 116. Trabelsi M-S, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino 
A, Brighton CA, Sebti Y, Kluza J, et al. Farnesoid X receptor inhibits 
glucagon-like peptide-1 production by enteroendocrine L cells. Nat 
Commun. 2015;6:7629.
 117. Dong B, Young M, Liu X, Singh AB, Liu J. Regulation of lipid metabo-
lism by obeticholic acid in hyperlipidemic hamsters. J Lipid Res. 
2017;58(2):350–63.
 118. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh 
PJ. Predicting and manipulating cardiac drug inactivation by the human 
gut bacterium Eggerthella lenta. Science. 2013;341(6143):295–8.
 119. Haiser HJ, Seim KL, Balskus EP, Turnbaugh PJ. Mechanistic insight into 
digoxin inactivation by Eggerthella lenta augments our understanding 
of its pharmacokinetics. Gut Microbes. 2014;5(2):233–8.
 120. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, 
Harris HMB, Coakley M, Lakshminarayanan B, O’Sullivan O, et al. Gut 
microbiota composition correlates with diet and health in the elderly. 
Nature. 2012;488(7410):178–84.
 121. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, 
Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, et al. Randomised clinical 
trial: lactobacillus GG modulates gut microbiome, metabolome and 
endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 
2014;39(10):1113–25.
 122. Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee Ying S, De Vadder F, 
Arora T, Hallen A, Martens E, Björck I, Bäckhed F. Dietary fiber-induced 
improvement in glucose metabolism is associated with increased 
abundance of Prevotella. Cell Metab. 2015;22(6):971–82.
 123. Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137(3 Suppl 
2):830s–7s.
 124. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, DuGar B, Feld-
stein AE, Britt EB, Fu X, Chung Y-M, et al. Gut flora metabolism of 
phosphatidylcholine promotes cardiovascular disease. Nature. 
2011;472(7341):57–63.
 125. Bennett Brian J, Vallim Thomas Qde A, Wang Z, Shih Diana M, Meng Y, 
Gregory J, Allayee H, Lee R, Graham M, Crooke R, et al. Trimethylamine-
N-oxide, a metabolite associated with atherosclerosis, exhibits complex 
genetic and dietary regulation. Cell Metab. 2013;17(1):49–60.
 126. Collison M, Hirt RP, Wipat A, Nakjang S, Sanseau P, Brown JR. Data min-
ing the human gut microbiota for therapeutic targets. Brief Bioinform. 
2012;13:751–68.
 127. Rajkumar H, Mahmood N, Kumar M, Varikuti SR, Challa HR, Myakala SP. 
Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitiv-
ity, inflammatory markers, and gut colonization in overweight adults: a 
randomized controlled trial. Mediat Inflamm. 2014;2014:8.
 128. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, 
Ballantyne CM, Somaratne R, Legg J, Wasserman SM, et al. Efficacy and 
safety of evolocumab in reducing lipids and cardiovascular events. N 
Engl J Med. 2015;372(16):1500–9.
 129. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, 
Kayser BD, Levenez F, Chilloux J, Hoyles L, et al. Akkermansia mucin-
iphila and improved metabolic health during a dietary intervention in 
obesity: relationship with gut microbiome richness and ecology. Gut. 
2016;65(3):426–36.
 130. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat 
D, Corthier G, Dore J, Henegar C, et al. Differential adaptation of 
human gut microbiota to bariatric surgery-induced weight loss: 
links with metabolic and low-grade inflammation markers. Diabetes. 
2010;59(12):3049–57.
 131. Borgo F, Verduci E, Riva A, Lassandro C, Riva E, Morace G, Borghi E. Rela-
tive abundance in bacterial and fungal gut microbes in obese children: 
a case control study. Child Obes. 2016.
 132. Karlsson CLJ, Önnerfält J, Xu J, Molin G, Ahrné S, Thorngren-Jerneck K. 
The microbiota of the gut in preschool children with normal and exces-
sive body weight. Obesity. 2012;20(11):2257–61.
 133. Vinjé S, Stroes E, Nieuwdorp M, Hazen SL. The gut microbiome 
as novel cardio-metabolic target: the time has come! Eur Heart J. 
2014;35(14):883–7.
Page 12 of 12Ryan et al. Diabetol Metab Syndr  (2017) 9:102 
 134. Maruvada P, Leone V, Kaplan LM, Chang EB. The human microbi-
ome and obesity: moving beyond associations. Cell Host Microbe. 
2017;22(5):589–99.
 135. Sawicki MP, Samara G, Hurwitz M, Passaro E. Human genome project. 
Am J Surg. 1993;165(2):258–64.
 136. Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from 
biomarker discovery to clinical utility in predictive and personalised 
medicine. EPMA J. 2013;4(1):1–10.
 137. Rose N. Personalized medicine: promises, problems and perils of a new 
paradigm for healthcare. Procedia Soc Behav Sci. 2013;77:341–52.
 138. Mardinoglu A, Boren J, Smith U. Confounding effects of metformin 
on the human gut microbiome in type 2 diabetes. Cell Metab. 
2016;23(1):10–2.
 139. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng Z-B, Wiest MM, Nguyen UT, 
Wojnoonski K, Watkins SM, Trupp M, Krauss RM. Enteric microbiome 
metabolites correlate with response to simvastatin treatment. PLoS 
ONE. 2011;6(10):e25482.
 140. Antman EM, Cohen M, Bernink PM, et al. The TIMI risk score for unstable 
angina/non–st elevation mi: a method for prognostication and thera-
peutic decision making. JAMA. 2000;284(7):835–42.
 141. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, 
Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. Diet 
rapidly and reproducibly alters the human gut microbiome. Nature. 
2014;505(7484):559–63.
 142. Clarke SF, Murphy EF, O’Sullivan O, Lucey AJ, Humphreys M, Hogan 
A, Hayes P, O’Reilly M, Jeffery IB, Wood-Martin R, et al. Exercise and 
associated dietary extremes impact on gut microbial diversity. Gut. 
2014;63(12):1913–20.
 143. Barton W, Penney NC, Cronin O, Garcia-Perez I, Molloy MG, Holmes 
E, Shanahan F, Cotter PD, O’Sullivan O. The microbiome of profes-
sional athletes differs from that of more sedentary subjects in 
composition and particularly at the functional metabolic level. Gut. 
2017;30(313627):2016–313627.
 144. Liu F, Prabhakar M, Ju J, Long H, Zhou HW. Effect of inulin-type fructans 
on blood lipid profile and glucose level: a systematic review and meta-
analysis of randomized controlled trials. Eur J Clin Nutr. 2016.
 145. Xu Z, Knight R. Dietary effects on human gut microbiome diversity. Br J 
Nutr. 2015;113(S1):S1–5.
 146. Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, Gao Z, Mahana D, 
Raju K, Teitler I. Antibiotics in early life alter the murine colonic microbi-
ome and adiposity. Nature. 2012;488(7413):621–6.
 147. Zhang HM, Wang X, Wu ZH, Liu HL, Chen W, Zhang ZZ, Chen D, Zeng 
TS. Beneficial effect of farnesoid X receptor activation on metabolism in 
a diabetic rat model. Mol Med Rep. 2016;13(3):2135–42.
 148. Liu X, Xue R, Ji L, Zhang X, Wu J, Gu J, Zhou M, Chen S. Activation of 
farnesoid X receptor (FXR) protects against fructose-induced liver stea-
tosis via inflammatory inhibition and ADRP reduction. Biochem Biophys 
Res Commun. 2014;450(1):117–23.
 149. Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, 
Gardell SJ, Huard C, Martinez R, Vlasuk GP, et al. A synthetic farnesoid X 
receptor (FXR) agonist promotes cholesterol lowering in models of dys-
lipidemia. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G543–52.
 150. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, 
Edwards PA. Activation of the nuclear receptor FXR improves hyper-
glycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 
2006;103(4):1006–11.
 151. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst 
A, Abdelkarim M, Caron S, Torpier G, Fruchart J-C, Gonzalez FJ, et al. 
The farnesoid X receptor modulates adiposity and peripheral insulin 
sensitivity in mice. J Biol Chem. 2006;281(16):11039–49.
 152. Corbeil P, Bloem BR, van Meel M, Maki BE. Arm reactions evoked by 
the initial exposure to a small balance perturbation: a pilot study. Gait 
Posture. 2013;37(2):300–3.
 153. Gardès C, Chaput E, Staempfli A, Blum D, Richter H, Benson GM. Dif-
ferential regulation of bile acid and cholesterol metabolism by the 
farnesoid X receptor in Ldlr (−/−) mice versus hamsters. J Lipid Res. 
2013;54(5):1283–99.
 154. Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, 
Gardell SJ, Huard C, Martinez R, Vlasuk GP, et al. A synthetic farnesoid 
X receptor (FXR) agonist promotes cholesterol lowering in models of 
dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):8.
 155. Xu Y, Li F, Zalzala M, Xu J, Gonzalez FJ, Adorini L, Lee YK, Yin L, Zhang Y. 
Farnesoid X receptor activation increases reverse cholesterol transport 
by modulating bile acid composition and cholesterol absorption in 
mice. Hepatology. 2016;64(4):1072–85.
 156. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo 
A, Yamamoto H, Mataki C, Pruzanski M, et al. TGR5-mediated bile acid 
sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167–77.
